Digital PET/CT using Vereos can spot the smallest lesion in a patient’s body. It is built with a digital detector to improve the sensitivity and detectability of small lesions while reducing the scan time. This hybrid imaging modality known as Vereos PET/CT from Philips Healthcare is used as a diagnostic and prognostic imaging tool by oncologists to assess the response of patients to therapy and even cancer recurrence. By digitalizing PET/CT, its medical value has increased tremendously.
Here’s how the Vereos PET/CT can enhance clinical care:
- Increased scan volume – The new imaging technique can enhance patient experience with excellent scan accuracy. The Vereos PET/CT has also increased the scan volume to 18 patients each day with whole-body scans taking 30 minutes. The high sensitivity of the digital detector and short scan times ensure quality images.
- Improved detectability for small lesions – The Vereos PET/CT can detect the small lesions and their activity in the body. This allows oncologists to stage or monitor a patient’s cancer and develop an appropriate treatment plan. It can also detect recurrent cancer and characterize the patient’s response to treatment.
- Helps in proper patient management – The digital PET images can be fused with CT scan images to produce colorized fused images that improve discussions between clinicians. This enables clear communication especially when specialists are planning on how to manage patients in tough cancer cases. When treatment options are not straightforward, the clinicians can localize the exact place the lesion is and make better treatment decisions.
The digital photon-counting detector that is built within the Vereos PET/CT will have more significant clinical benefits in radiation oncology. The relative certainty offered by the digital detector has increased the clinical prospects of PET/CT. More collaborative projects are underway to use Vereos in digital imaging and also implement molecular imaging in the future.